Skip to main content
SpringerLink
Log in

Identification of serum biomarkers for ovarian cancer using MALDI–TOF-MS combined with magnetic beads

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The objective of this study was to search for potential protein biomarkers in serum for diagnosis of ovarian cancer, by use of proteomic fingerprint techniques.

Method

MALDI–TOF-MS was combined with magnetic beads to profile and compare serum protein spectra from 40 ovarian cancer patients and from 60 healthy controls.

Results

The tree analysis model of potential cancer biomarkers was constructed with Biomarker Patterns software on the basis of three identified biomarkers (5486, 6440, and 13720 Da), resulting in excellent discrimination between the ovarian cancer and non-cancer in our tests. The sensitivity was 90% and the specificity was 86.7%. In a blind test the sensitivity was 88% and the specificity was 83.3%.

Conclusion

The results suggested that biomarkers for ovarian cancer diagnosis in serum could be identified by MALDI–TOF-MS combined with the use of magnetic beads. The use of combined biomarkers would further enable powerful and reliable diagnosis of ovarian cancer with high sensitivity and specificity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Posadas EM, Davidson B, Kohn EC (2004) Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr Opin Oncol 16(5):478–484

    Article  PubMed  CAS  Google Scholar 

  2. Whitehouse C, Solomon E (2003) Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 88:S152–S157

    Article  PubMed  CAS  Google Scholar 

  3. Høgdall E, Fung ET, Christensen IJ et al (2010) Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteomics Clin Appl 4(12):940–952

    Article  PubMed  Google Scholar 

  4. Brazert J, Pietryga M, Szabłoński W et al (2003) Diagnostic value of the morphological ultrasound score system and the serum concentration of CA125 in the diagnosis of malignant ovarian cancer. Ginekol Pol 74(12):1542–1548

    PubMed  Google Scholar 

  5. van der Merwe DE, Oikonomopoulou K, Marshall J et al (2007) Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 96:23–50

    Article  PubMed  Google Scholar 

  6. Breedlove G, Busenhart C (2005) Screening and detection of ovarian cancer. J Midwifery Women’s Health 50(8):51–54

    Article  Google Scholar 

  7. Ward DG, Suggett N, Cheng Y et al (2006) Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94:1898–1905

    Article  PubMed  CAS  Google Scholar 

  8. Hortin GL (2006) The MALDI–TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52:1223–1237

    Article  PubMed  CAS  Google Scholar 

  9. Liu C, Pan C, Shen J et al (2011) MALDI–TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer. Int J Med Sci 8:39–47

    Article  PubMed  CAS  Google Scholar 

  10. Liang Y, Fang M, Li J et al (2006) Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol 81:176–180

    Article  PubMed  CAS  Google Scholar 

  11. Liu CB, Liang Y, Pan CQ et al (2009) Proteome study of differential protein expression in HBV-related primary hepatic carcinoma. Chem J Chin Univ 30:1763–1766

    CAS  Google Scholar 

  12. Petricoin EF, Ardekani AM, Hitt BA et al (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306):572–577

    Google Scholar 

  13. Kozak KR, Amneus MW, Pusey SM et al (2003) Identification of biomarkers for ovarian cancer using strong anion-exchange protein chip: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 100:12343–12348

    Article  PubMed  CAS  Google Scholar 

  14. Rai AJ, Zhang Z, Rosenzweig J et al (2002) Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126(12):1518–1526

    PubMed  CAS  Google Scholar 

  15. Ye B, Cramer DW, Skates SJ et al (2003) Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9(8):2904–2911

    PubMed  CAS  Google Scholar 

  16. Zhang Z, Bast RC Jr, Yu Y et al (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64(16):5882–5890

    Article  PubMed  CAS  Google Scholar 

  17. Li YZ, Hu CJ, Leng XM et al (2009) Promising diagnostic biomarkers for primary biliary cirrhosis identified with magnetic beads and MALDI–TOF-MS. Anat Rec (Hoboken) 292:455–460

    Article  CAS  Google Scholar 

  18. Guo R, Pan C, Shen J et al (2011) New serum biomarkers for detection of esophageal carcinoma using Matrix‐assisted laser desorption/ionization time-of-flight mass spectrometry. J Cancer Res Clin Oncol 137:513–519

    Article  PubMed  CAS  Google Scholar 

  19. Liu C, Shen J, Pan C et al (2010) MALDI–TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol 134:235–241

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

  1. Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, Zhejiang, China

    Shengjun Wu, Guang Chen, Jun Zhang, Zhiwei Liu & Xinyou Xie

  2. The Third People’s Hospital of Wenzhou, Wenzhou, Zhejiang, China

    Kai Xu

Authors
  1. Shengjun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kai Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiwei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xinyou Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shengjun Wu.

About this article

Cite this article

Wu, S., Xu, K., Chen, G. et al. Identification of serum biomarkers for ovarian cancer using MALDI–TOF-MS combined with magnetic beads. Int J Clin Oncol 17, 89–95 (2012). https://doi.org/10.1007/s10147-011-0259-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-011-0259-6

Keywords

Search

Navigation